The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma
Open accessAbstract
Purpose: To uncover the genetic events leading to transformation of pediatric low-grade glioma (PLGG) to secondary high-grade glioma (sHGG). Patients and Methods: We retrospectively identified patients with sHGG from a population-based cohort of 886 patients with PLGG with long clinical follow-up. Exome sequencing and array CGH were performed on available samples followed by detailed genetic analysis of the entire sHGG cohort. Clinical and outcome data of genetically distinct subgroups were obtained. Results: sHGG was observed in 2.9% of PLGGs (26 of 886 patients). Patients with sHGG had a high frequency of nonsilent somatic mutations compared with patients with primary pediatric high-grade glioma (HGG; median, 25 mutations per exome; P = .0042). Alterations in chromatin-modifying genes and telomere-maintenance pathways were commonly observed, whereas no sHGG harbored the BRAF-KIAA1549 fusion. The most recurrent alterations were BRAF V600E and CDKN2A deletion in 39% and 57% of sHGGs, respectively. Importantly, all BRAF V600E and 80% of CDKN2A alterations could be traced back to their PLGG counterparts. BRAF V600E distinguished sHGG from primary HGG (P = .0023), whereas BRAF and CDKN2A alterations were less commonly observed in PLGG that did not transform (P < .001 and P < .001 respectively). PLGGs with BRAF mutations had longer latency to transformation than wild-type PLGG (median, 6.65 years [range, 3.5 to 20.3 years] v 1.59 years [range, 0.32 to 15.9 years], respectively; P = .0389). Furthermore, 5-year overall survival was 75% ± 15% and 29% ± 12% for children with BRAF mutant and wild-type tumors, respectively (P = .024). Conclusion: BRAF V600E mutations and CDKN2A deletions constitute a clinically distinct subtype of sHGG. The prolonged course to transformation for BRAF V600E PLGGs provides an opportunity for surgical interventions, surveillance, and targeted therapies to mitigate the outcome of sHGG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Genotyping for candidate hotspot mutations was carried out as previously described.(10,15,23,24) Specific CNAs were validated by realtime quantitative polymerase chain reaction.”
MethodThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631 · cited 1×
“Different studies reveal rates between 10% and 25%.(11,31-33) Our observations resolve some of these discrepancies, because the mutation may be specific to the subgroup of secondary pediatric HGG rather than primary pediatric HGG.”
BackgroundSelf-citationMalignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Self-citationHighly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028 · cited 1×
“3 K27M mutations.(37,38) In both scenarios, the addition of molecular markers as described in this study may help to establish (eg, BRAFKIAA1549 fusion) or refute (eg, H3F3A mutation) the PLGG diagnosis.”
BackgroundSelf-citationJones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Bäcklund, L. M., Ichimura, K., & Collins, V. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2097 · Cited by 944
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2013) · Nature Genetics · doi:10.1038/ng.2611 · Cited by 835
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Self-citationGarnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Paugh, B. S., Qu, C., Jones, C., Liu, Z., Adamowicz-Brice, M., Zhang, J., Bax, D. A., Coyle, B., Barrow, J., Hargrave, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7252 · Cited by 654
Buczkowicz, P., Hoeman, C., Rakopoulos, P., Pajovic, S., Letourneau, L., Dzamba, M., Morrison, A., Lewis, P., Bouffet, E., Bartels, U., et al. (2014) · Nature Genetics · doi:10.1038/ng.2936 · Cited by 647
Self-citationPrimary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 529
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas
Pfister, S., Janzarik, W. G., Remke, M., Ernst, A., Werft, W., Becker, N., Toedt, G., Wittmann, A., Kratz, C., Olbrich, H., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33656 · Cited by 523
Self-citationDNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity
Henson, J. D., Cao, Y., Huschtscha, L. I., Chang, A. C., Au, A. Y. M., Pickett, H. A., & Reddel, R. R. (2009) · Nature Biotechnology · doi:10.1038/nbt.1587 · Cited by 498
BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
Cantwell-Dorris, E. R., O'Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 459
Sharif, S., Ferner, R., Birch, J. M., Gillespie, J. E., Gattamaneni, H. R., Baser, M. E., & Evans, D. G. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8349 · Cited by 377
Buczkowicz, P., Bartels, U., Bouffet, E., Becher, O., & Hawkins, C. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1319-6 · Cited by 350
Self-citationMutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Paugh, B. S., Broniscer, A., Qu, C., Miller, C. P., Zhang, J., Tatevossian, R. G., Olson, J. M., Geyer, J. R., Chi, S. N., da Silva, N. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5677 · Cited by 320
Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017948 · Cited by 315
Self-citationZarghooni, M., Bartels, U., Lee, E., Buczkowicz, P., Morrison, A., Huang, A., Bouffet, E., & Hawkins, C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5463 · Cited by 313
Self-citationFontebasso, A. M., Schwartzentruber, J., Khuong-Quang, D.-A., Liu, X.-Y., Sturm, D., Korshunov, A., Jones, D. T. W., Witt, H., Kool, M., Albrecht, S., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1095-8 · Cited by 290
Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H., Chan, T. A., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 278
BRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
Sievert, A. J., Jackson, E. M., Gai, X., Hakonarson, H., Judkins, A. R., Resnick, A. C., Sutton, L. N., Storm, P. B., Shaikh, T. H., & Biegel, J. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00225.x · Cited by 255
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M.-Y. C., Yu, M., Fisher, P. G., Rowitch, D. H., Ford, J. M., Berger, M. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1851 · Cited by 251
BRAF-KIAA1549 Fusion Predicts Better Clinical Outcome in Pediatric Low-Grade Astrocytoma
Hawkins, C., Walker, E., Mohamed, N., Zhang, C., Jacob, K., Shirinian, M., Alon, N., Kahn, D., Fried, I., Scheinemann, K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0034 · Cited by 250
Self-citationPuget, S., Philippe, C., Bax, D. A., Job, B., Varlet, P., Junier, M.-P., Andreiuolo, F., Carvalho, D., Reis, R., Guerrini-Rousseau, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030313 · Cited by 242
Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children
Broniscer, A., Baker, S. J., West, A. N., Fraser, M. M., Proko, E., Kocak, M., Dalton, J., Zambetti, G. P., Ellison, D. W., Kun, L. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8213 · Cited by 237
Bakry, D., Aronson, M., Durno, C., Rimawi, H., Farah, R., Alharbi, Q. K., Alharbi, M., Shamvil, A., Ben-Shachar, S., Mistry, M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.005 · Cited by 233
Self-citationBroniscer, A., & Gajjar, A. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-197 · Cited by 225
Faury, D., Nantel, A., Dunn, S. E., Guiot, M.-C., Haque, T., Hauser, P., Garami, M., Bognár, L., Hanzély, Z., Liberski, P. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8626 · Cited by 225
Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital.
Gajjar, A., Sanford, R. A., Heideman, R., Jenkins, J. J., Walter, A., Li, Y., Langston, J. W., Muhlbauer, M., Boyett, J. M., & Kun, L. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2792 · Cited by 224
Qaddoumi, I., Sultan, I., & Gajjar, A. (2009) · Cancer · doi:10.1002/cncr.24663 · Cited by 218
Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells
Koelsche, C., Wöhrer, A., Jeibmann, A., Schittenhelm, J., Schindler, G., Preusser, M., Lasitschka, F., von Deimling, A., & Capper, D. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1100-2 · Cited by 191
Age–incidence patterns of primary CNS tumors in children, adolescents, and adults in England
Arora, R. S., Alston, R. D., Eden, T. O. B., Estlin, E. J., Moran, A., & Birch, J. M. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-097 · Cited by 181
BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma
Dahiya, S., Haydon, D. H., Alvarado, D., Gurnett, C. A., Gutmann, D. H., & Leonard, J. R. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1120-y · Cited by 169
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Remke, M., Ramaswamy, V., Peacock, J., Shih, D. J. H., Koelsche, C., Northcott, P. A., Hill, N., Cavalli, F. M. G., Kool, M., Wang, X., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1198-2 · Cited by 164
Self-citationMerchant, T. E., Rose, S. R., Bosley, C., Wu, S., Xiong, X., & Lustig, R. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.9453 · Cited by 162
Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues
Pei, X.-H., & Xiong, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208611 · Cited by 158
Targeted Therapy for BRAFV600E Malignant Astrocytoma
Nicolaides, T. P., Li, H., Solomon, D. A., Hariono, S., Hashizume, R., Barkovich, K. J., Baker, S. J., Paugh, B. S., Jones, C., Forshew, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1456 · Cited by 154
The Somatic Genomic Landscape of Glioblastoma
Brennan, C., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, Z., Berman, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.04.004 · Cited by 142
Pollack, I. F., Finkelstein, S. D., Burnham, J. A., Holmes, E. J., Hamilton, R. L., Yates, A. J., Finlay, J. L., & Sposto, R. (2001) · PubMed · Cited by 138
Brainstem Ganglioglioma Successfully Treated With Vemurafenib
Rush, S. Z., Foreman, N. K., & Liu, A. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1568 · Cited by 129
Qu, H., Jacob, K., Fattet, S., Ge, B., Barnett, D., Delattre, O., Faury, D., Montpetit, A., Solomon, L. A., Hauser, P., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop001 · Cited by 119
Self-citationWeber, R. G., Hoischen, A., Ehrler, M., Zipper, P., Kaulich, K., Blaschke, B., Becker, A. J., Weber‐Mangal, S., Jauch, A. T., Radlwimmer, B., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209851 · Cited by 118
Barrow, J., Adamowicz‐Brice, M., Cartmill, M., Macarthur, D., Lowe, J. S., Robson, K., Bründler, M., Walker, D. A., Coyle, B., & Grundy, R. G. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq158 · Cited by 116
Chemotherapy for Malignant Brain Tumors of Childhood
Gottardo, N. G., & Gajjar, A. J. (2008) · Journal of Child Neurology · doi:10.1177/0883073808321765 · Cited by 104
Yunoue, S., Tokuo, H., Fukunaga, K., Feng, L., Ozawa, T., Nishi, T., Kikuchi, A., Hattori, S., Kuratsu, J., Saya, H., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209413200 · Cited by 100
EWS/FLI-1 Induces Rapid Onset of Myeloid/Erythroid Leukemia in Mice
Torchia, E. C., Boyd, K. L., Rehg, J. E., Qu, C., & Baker, S. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-07 · Cited by 94
Detection of alternative lengthening of telomeres by telomere quantitative PCR
Lau, L. M. S., Dagg, R. A., Henson, J. D., Au, A. Y. M., Royds, J. A., & Reddel, R. R. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks781 · Cited by 93
Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas
Newcomb, E. W., Alonso, M., Sung, T., & Miller, D. C. (2000) · Human Pathology · doi:10.1016/s0046-8177(00)80207-5 · Cited by 82
Antonelli, M., Buttarelli, F. R., Arcella, A., Nobusawa, S., Donofrio, V., Oghaki, H., & Giangaspero, F. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0129-5 · Cited by 78
Early deaths in pediatric acute leukemia: a population-based study
Cheng, S. S., Pole, J. D., & Sung, L. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.850685 · Cited by 28
Self-citationSyndromes Predisposing to Pediatric Central Nervous System Tumors: Lessons Learned and New Promises
Villani, A., Malkin, D. M., & Tabori, U. Y. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0244-5 · Cited by 26
Self-citation
Cited by
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Nabors, L. B., Portnow, J., Ahluwalia, M., Baehring, J., Brem, H., Brem, S., Butowski, N., Campian, J. L., Clark, S. W., Fabiano, A. J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0052 · Cited by 539
Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
Ryall, S., Zapotocky, M., Fukuoka, K., Nobre, L., Guerreiro Stucklin, A., Bennett, J., Siddaway, R., Li, C., Pajovic, S., Arnoldo, A., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.011 · Cited by 474
Self-citationAlterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Guerreiro Stucklin, A. S., Ryall, S., Fukuoka, K., Zapotocky, M., Lassaletta, A., Li, C., Bridge, T., Kim, B., Arnoldo, A., Kowalski, P. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12187-5 · Cited by 367
Self-citationPediatric high-grade glioma: biologically and clinically in need of new thinking
Jones, C., Karajannis, M. A., Jones, D. T. W., Kieran, M. W., Monje, M., Baker, S. J., Becher, O. J., Cho, Y.-J., Gupta, N., Hawkins, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now101 · Cited by 360
Self-citationPediatric low-grade glioma in the era of molecular diagnostics
Ryall, S., Tabori, U., & Hawkins, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00902-z · Cited by 351
Self-citation
Metadata
- Authors
- Mistry, M., Zhukova, N., Merico, D., Rakopoulos, P., Krishnatry, R., Shago, M., Stavropoulos, J., Alon, N., Pole, J. D., Ray, P. N., Navickiene, V., Mangerel, J., Remke, M., Buczkowicz, P., Ramaswamy, V., Guerreiro Stucklin, A., Li, M., Young, E. J., Zhang, C., Castelo-Branco, P., Bakry, D., Laughlin, S., Shlien, A., Chan, J., Ligon, K. L., Rutka, J. T., Dirks, P. B., Taylor, M. D., Greenberg, M., Malkin, D., Huang, A., Bouffet, E., Hawkins, C. E., & Tabori, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-03-20
- Volume
- 33
- Issue
- 9
- Pages
- 1015-1022
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115078134
- Cited by
- 288
- References
- 71
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.